Abstract | PURPOSE: METHODS: Meta-analyses assessing the association of MTHFR C677T and A1298C variations with AML and CML were conducted. Eligible articles were identified from the PubMed and EMBASE databases. All statistical analyses were conducted using Review Manager Software. RESULTS: 10 and 10 studies were included in the meta-analysis about the role of C677T polymorphism on the AML and CML risks, respectively; 6 and 4 studies were included about the role of A1298C polymorphism on the AML and CML risks, respectively. Overall, both the C677T and A1298C polymorphisms were significantly associated with CML risk under the recessive model (P=0.04, OR=1.35, 95% CI=1.02-1.79 for C677T and P=0.003, OR=2.17, 95% CI=1.29-3.63 for A1298C). In addition, the risk of CML was higher in 1298CC genotype carriers than in 1298AA genotype carriers (P=0.004, OR=2.17, 95%=1.28-3.69). Conversely, the overall data failed to indicate a significant association of C677T or A1298C polymorphisms with AML risk under any model. CONCLUSIONS: The findings provide evidence that C677T and A1298C polymorphisms are risk factors for CML risk.
|
Authors | Hairong He, Gonghao He, Taotao Wang, Jiangxia Cai, Yan Wang, Xiaowei Zheng, Yalin Dong, Jun Lu |
Journal | Cancer epidemiology
(Cancer Epidemiol)
Vol. 38
Issue 5
Pg. 471-8
(Oct 2014)
ISSN: 1877-783X [Electronic] Netherlands |
PMID | 25080853
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 Elsevier Ltd. All rights reserved. |
Chemical References |
- Methylenetetrahydrofolate Reductase (NADPH2)
|
Topics |
- Genetic Predisposition to Disease
- Genotype
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(genetics)
- Leukemia, Myeloid, Acute
(genetics)
- Methylenetetrahydrofolate Reductase (NADPH2)
(genetics)
- Polymorphism, Genetic
- Risk Factors
|